CTLA4 and neoplasm: Intratumoral administration of engineered NDV LaSota expressing ICOSL resulted in enhanced infiltration of CD8+ and CD4+ T cells, tumor growth delay of both injected and non-injected tumors, and prolonged survival, as compared to wild type NDV, and this effect that was further enhanced when combined with anti-CTLA-4 blockade [60].